Gathering the record
Relay is organizing the evidence and source boundaries.
Experimental ERR agonist small molecule
An experimental compound discussed for endurance and fat metabolism. It is a small molecule, not a peptide.
Evidence is explained by question. Dosing references show their own check dates.
60-second overview
Why people look into it, what studies found, and what is still unknown.
Educational information only. Evidence reviewed through July 31, 2026. Published studies, sponsor announcements, and trials without results are labeled separately. Evidence gaps apply to the specific finding beside them.
Research questions
Each label shows how much evidence supports that question.
What studies show
No administered-human study was located.
This is the strongest human-evidence boundary in the current record.
Mechanistic findings explain biological plausibility; they do not establish a human outcome.
Relay keeps this uncertainty visible rather than converting it into a prediction.
The safety snapshot reflects the studied record and its limitations.
Regulatory and identity status determine how the evidence should be interpreted.
Risks & unknowns
Current evidence cannot yet resolve: Human pharmacokinetics, selectivity, target engagement, efficacy, organ toxicity, reproductive effects, and long-term safety.
No direct evidenceAn absence of adequate evidence is not evidence of benefit, harm, or equivalence.
Open sourceThe available information does not reliably show how often particular side effects occur.
Evidence boundaryUnder-detected or under-reported events must not be described as rare.
Relay has not verified which side effects led people to stop treatment in studies.
Evidence boundaryThis is an evidence gap, not proof that discontinuations did not occur.
Relay has not verified a compound-specific warning summary for this profile.
Evidence boundaryPreclinical; no FDA-approved product and no administered-human outcome study located. Human pharmacokinetics, selectivity, target engagement, efficacy, organ toxicity, reproductive effects, and long-term safety.
This profile does not contain verified, product-specific emergency instructions.
Evidence boundaryRelay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Dosing references
Each table labels its source and applies only to the named route, product, or study. An online example or community report is not an approved dose.
The reviewed exercise-mimetic evidence is from preclinical research. It does not establish a human dose, route, or safe exposure range.
What would fill this gap: A verified human trial of SLU-PP-332, rather than animal-to-human dose conversion.
Dosing review checked Oct 20, 2026. Additional sources are available below.No route-specific preparation instructions were verified. A different route or product does not supply them.
Starting dose: the amount used at the beginning of the named label schedule or trial.
Maintenance: the ongoing amount described by that product label.
Trial target: the amount assigned to a study group. Different groups may stop increasing at different targets.
Published research investigated SLU-PP-332 in sedentary mice and measured endurance alongside oxidative muscle-fiber and metabolic changes.
Population: Mice
Design: Controlled animal study
Mechanisms
Mouse studies report oxidative-muscle, endurance, and metabolic changes. Later analog work specifically sought better oral exposure, underscoring that the parent compound is not a clinically validated oral therapy.
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
Research reference
A reference for the studies, populations, and routes behind this profile.
Animal and mechanistic evidence only; parent compound has oral-bioavailability limitations.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
Human pharmacokinetics, selectivity, target engagement, efficacy, organ toxicity, reproductive effects, and long-term safety.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: No verified study administered SLU-PP-332 to human participants. Mouse endurance and metabolism outcomes cannot establish human performance, exercise replacement, clinical benefit, pharmacokinetics, or safety. Amounts shown describe cited research exposure—not a dosage recommendation.
Studies
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Controlled animal study
Mice
SLU-PP-332 increased oxidative muscle fibers and endurance in sedentary mice.
Study administration: SLU-PP-332 versus vehicle
Limitations: Mouse study using experimental exposure; no human outcomes.
Controlled animal metabolic study
Mouse obesity models
Endpoints were not fully described in the current record.
Mouse experiments reported increased energy expenditure and improved selected metabolic measures.
Study administration: Not stated in the current record.
Limitations: Animal-model and exposure differences limit translation.
Medicinal chemistry and preclinical pharmacology study
Population not stated.
Endpoints were not fully described in the current record.
New analogs were developed to address limitations including oral exposure of the parent research tool.
Study administration: Not stated in the current record.
Limitations: Analog findings do not validate SLU-PP-332 or establish human use.
Community
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Sources
PMID 36988910
PMID 37739806
PMID 41421047